OncLive TV

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Mansoor Raza Mirza, MD, discusses the evolving treatment landscape in recurrent ovarian cancer.

Kathleen Moore, MD, discusses the current prevalence of ovarian cancer.

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

David R. Gandara, MD, discusses measuring tumor mutational burden in patients with non–small cell lung cancer who received prior immunotherapy.

Karen Kelly, MD, discusses encouraging preliminary data with neoadjuvant immunotherapy in lung cancer.

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.

Jeanne M. Palmer, MD, discusses the prognosis and challenges of predicting graft-versus-host disease in patients who have undergone transplant.

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.